
SemBioSys Produces Commercial Levels of Recombinant Apo AI Using Plants
SemBioSys Genetics, Inc. (Calgary, Canada, www.sembiosys.com) announced that it has successfully produced commercial levels of apolipoprotein AI and its variant apolipoprotein AI(Milano), collectively referred to as Apo AI, in safflower seed lines.
SemBioSys Genetics, Inc. (Calgary, Canada,
SemBioSys says its plant-produced Apo AI offers the potential to overcome the manufacturing challenges of traditional fermentation-based technologies. SemBioSys’s technology addresses protein extraction and purification, as well as bulk protein production. Using this new technology, SemBioSys estimates that it can reduce capital costs for protein production by up to 70% and cost of goods by 40% or more.
SemBioSys expects to confirm the in vivo efficacy of plant-produced Apo AI in the third quarter of 2007. The company then intends to scale up production of plant-produced Apo AI and perform the necessary preclinical work in 2008 in order to initiate clinical trials in 2009.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.